Quick Answer
Mineralys Therapeutics, Inc. reported R&D Expense of $132.01 million for fiscal year 2025.
Mineralys Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $132.01M | -21.7% |
| 2024 | $168.58M | +139.6% |
| 2023 | $70.36M | +168.0% |
| 2022 | $26.25M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $31.45M | -41.7% | -17.8% |
| June 30, 2025 | $38.28M | -2.5% | +1.1% |
| March 31, 2025 | $37.88M | +23.2% | -29.8% |
| September 30, 2024 | $53.98M | +139.9% | +37.5% |
| June 30, 2024 | $39.27M | +230.5% | +27.7% |
| March 31, 2024 | $30.75M | +150.2% | +36.7% |
| September 30, 2023 | $22.50M | +271.3% | +89.3% |
| June 30, 2023 | $11.88M | +112.4% | -3.3% |
- Mineralys Therapeutics, Inc. showed a decrease of -21.7% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Mineralys Therapeutics, Inc.’s r&d expense has grown by 402.9% (from $26.25 million to $132.01 million).
- The most recent figure is from Mineralys Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: